 MONT-SAINT-GUIBERT, Belgium, March 17, 2022 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that the Company will report full year 2021 financial and operating results on the evening of Thursday, March 24th. 